BRASTER has signed a contract on production of second-generation registering transducers together with ergonomic shells. These devices will be used to carry out examinations under the INNOMED project. Their development is another element of implementation of the strategy that foresees introducing BRASTER TESTER for sale for women in the second half of 2016. BRASTER S.A., which is now moving its quotations to the main market of the Warsaw Stock Exchange (WSE), is the owner of a unique technology for supporting breast cancer diagnostics.

The registering transducer is the key element of the BRASTER TESTER device. The functionalities of new-generation transducers will principally include registration of diagnostic thermographic images created on Braster matrices, wireless data transfer to tablets and monitoring the basic ambient parameters in the room where the examination is performed.

"According to the contractual provisions, the devices will be available for us in September this year at the latest and used to carry out examinations as part of the INNOMED project, implemented together with the Jagiellonian University,” – says President of the Management Board of BRASTER S.A. Marcin Halicki.

The INNOMED study is to enable the comparison of the BRASTER TESTER device in diagnostics and differentiation of pathologies in women’s breast against standard diagnostic methods (in line with a new algorithm). It will be carried out by the Medical College at the Jagiellonian University on a group of over 2,000 women. The project was co-financed by the National Centre for Research and Development in the amount of PLN 9.1 million (its total cost will amount to PLN 10.2 million).

The concluded contract foresees using 3D printing technology to prepare prototypes and, subsequently, production of 50 devices. As part of the work, the following elements are to be designed and manufactured: a digital electronic circuit divided into a registration module and an image-processing module, a power supply module, a wireless transfer module and a transducer shell, taking into account guidance on design and ergonomics. Functionality tests will be performed after realisation of the device prototypes.

"Through the work foreseen in the concluded contract, we will make a great step towards creation of a consumer version of BRASTER TESTER. Electronic components comprised in the new transducer will be very similar to the elements of the device that is to be placed on the market in 2016. Apart from the visual appearance of the device, the main difference will be that the thermographic images made in the INNOMED study will be analysed by physicians, whereas in the final version, their role will be taken over by precise algorithms of automatic image interpretation,” – explains Marcin Halicki.

The net value of the contract is PLN 344,000. The contractor is Creotech Instruments S.A., a reputable company creating electronic systems for Polish and foreign clients. This company implements i.a. projects relating to space research and exploration and provides components and specialist equipment for the most hi-tec research institutions, such as the European Organisation for Nuclear Research (CERN) in Geneva, the GSI Centre for Heavy Ion Research and the DESY Research Centre in Germany, the Space Research Centre at the Polish Academy of Sciences and the Warsaw University of Technology.

BRASTER implements a strategy foreseeing introduction of the BRASTER TESTER device for sale in the second half of 2016. In recent weeks, the Company launched construction of a complete thermographic matrix production line and started works on an application for automatic examination interpretation, carried out along with the Warsaw University of Technology. Since the beginning of the year, the BRASTER team has been expanded, welcoming experienced managers specialising in areas of production process organisation and IT in medicine.

At the end of January, BRASTER filed a request to the Polish Financial Supervision Authority for renewal of proceedings on approval of the Issuing Prospectus. The approval of the prospectus will allow the Company to move its quotations to the main market of the WSE.